| SR.NO |
NAME OF BACTERIAL STRAIN |
GENE EXPRESSED |
ENZYME |
DRUG PRODRUG |
MECHANISM OF ACTION |
TYPE OF CANCER CURED |
JOURNAL NAME |
| 1 |
Salmonella[37] |
HSV TK[37] |
thymidine kinase polypeptide[37] |
phosphorylation of the prodrugganciclovir[37] |
It inhibits deoxyguanosine triphosphate (dGTP) incorporation into DNA [62] |
Melanoma[37] |
The American Journal Of Cancer(1931-1940)[37] |
| 2. |
Escherichia coli [38] |
-------- |
uridinephosphorylase[38] |
Capecitabine (Xeloda, N4-pentyloxycarbonyl-5'deoxy-5-fluorocytidine)to anticancer agent 5-FU [38] |
It inhibit thymidylatesybthetazae enzyme[63]
It also block conversion of 5, 10-methylene tetrahydrofolate to dihydrofolate[63]
It also inhibit conversion of dUMP to dTMP which is necessary for DNAsynthesis[63]
|
Colon, rectum, and head and neck cancers.[38] |
Curr med chem[38] |
| 3 |
Mainly produced in rabbits which can be cloned in bacterium [39] |
---------- |
Carboxylesterase[39] |
TAX prodrugs, 2’-ethylcarbonate-linked paclitaxel [39] |
Bind with microtubules and stabilizes microtubule, thus block G2/M phase of cell cycle. [64] |
Ovarian cancer[39] |
------- |
| <4. |
E. coli [40] |
---------- |
Nitroreductase[40] |
Pro-drug CB 1954 is activated to the cytotoxic metabolite 5-aziridin-1-yl-4-hydroxylamino-2-nitrobenzamide [40] |
Highly toxic DNA cross linking agent [65] |
Lymphomas[1] |
Pharmacological reviews[40] |
| 5. |
Oceanobacillusiheyensis[51] |
------------ |
methionine synthase reductase (MTRR),aldo-ketoreductase 1C3 (AKR1C3 [41] |
CONVERSION OF PR-104 TO PR-104A [41] |
|
HEPATOCELLULAR CARCINOMA [41] |
Auckland Cancer Society Research Centre [41] |
| 6. |
Escherichia coliand Mycobacterium tuberculosis [42] |
-------- |
Nitric oxide synthases (NOSs) [42] |
5-(Aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) [42] |
Highly toxic DNA cross linking agent [65] |
Human ovarian cancer[19] |
ProcNatlAcadSci U S [42] |
| 7. |
Mainly prodced in rabbits which can be cloned in bacterium[18] |
----------- |
carboxyesterases enzyme[18] |
Convert Irinotecan (CPT11) to camptothecin (SN38)[18] |
|
Adeno carcinoma and squamous cell carcinoma[20] |
Recent trends in antcancer therapy[18] |
| 8. |
Present before development of malignancy in cancers [52] |
------- |
Matrixmetalloproteinases-2 [43] |
CBI-TMI (a duocarmycin class minor groove binder)[43] |
|
Brest cancer [43] |
Molecular pharmaceutics [43] |
| 9. |
Salmonella typhimurium strain SL7838-chrR6[12] |
------ |
ChrR6[44] |
6-chloro-9-nitro-5-oxo-5H-benzo(a)phenoxazine (CNOB).[44] |
|
Treat various tumor in mice[44] |
Molecular cancer ther[44] |
